






































































































































































































































	 1	 2	 3	 4	 5	 	I	prefer	compounded	medications	over	manufactured,	commercially	available	medications	
0	(0)	 6	(7.2)	 46	(55.4)	 12	(14.5)	 19	(22.9)	 3.53	(0.928)	
Getting	compounded	medications	leads	to	a	deeper	and	more	personal	relationship	with	my	pharmacist	
3	(3.6)	 5	(6.0)	 32	(38.6)	 25	(30.1)	 18	(21.7)	 3.60	(1.011)	
Getting	compounded	medications	leads	to	a	more	patient-centered,	rather	than	drug-centered	relationship	with	my	pharmacist.		
1	(1.7)	 4	(4.8)	 25	(30.1)	 25	(30.1)	 28	(33.7)	 3.90	(0.970)	
*	1	=	strongly	disagree	and	5	=	strongly	agree		 Respondents	were	also	asked	about	their	support	for	compounded	medications.	Answer	choices	were	the	same	as	the	question	before	it	that	asked	about	familiarity,	ranging	from	“extremely	supportive”	to	“not	at	all	supportive.”	There	was	also	a	sixth	option,	“I	don’t	know;	I	have	never	heard	about	pharmacy	compounding	before	taking	this	survey.”	The	majority	of	respondents	were	supportive	of	compounds,	with	36%	of	respondents	being	“very	supportive,”	and	34%	being	“extremely	supportive.”	Additional	data	can	be	found	in	Figure	6.			 Additional	analysis	was	done	to	determine	if	those	who	had	received	a	compound	within	the	family	were	more	supportive	of	compounded	medications	
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than	those	who	had	not.	The	respondents	were	split	into	two	groups:	those	who	had	compound	use	in	the	household,	and	those	who	had	no	connection	to	compounded	medications.	A	statistically	significant	difference	was	found	between	the	two	groups,	with	those	having	a	household	connection	to	compounded	medications	being	more	supportive	of	compounded	medications,		X2	(4,	N	=	134)	=	34.4,	p	<	.05	The	group	that	did	not	get	compounds	reported	more	“I	don’t	know”	and	“moderately	supportive”	answers	than	the	group	that	received	compounds.	No	participant	in	either	group	reported	being	unsupportive	of	compounded	medications.	Further	data	on	the	differences	in	answers	between	the	two	groups	can	be	found	in	Figures	7	and	8.			 Figure	6:	Support	for	Pharmacy	Compounds	(All	Respondents)	
			
Extremely	34%	
Very	36%	
Moderately	16%	
Slightly		4%	
I	Don't	Know	10%	
HOW	SUPPORTIVE	ARE	YOU	OF	
COMPOUNDED	MEDICATIONS?	
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Figure	7:	Support	for	Pharmacy	Compounds	by	Compound	Users	
		 Figure	8:	Support	for	Pharmacy	Compounds	by	Compound	Non-Users	
			
	
Extremely	43%	
Very	44%	
Moderately	11%	
Slightly		1%	 I	Don't	Know	1%	
HOW	SUPPORTIVE	ARE	YOU	OF	
COMPOUNDED	MEDICATIONS?	(GETS	
COMPOUNDS)	
Extremely	18%	
Very	24%	
Moderately	26%	
Slightly		8%	
I	Don't	Know	24%	
HOW	SUPPORTIVE	ARE	YOU	OF	
COMPOUNDED	MEDICATIONS?	(DOES	
NOT	GET	COMPOUNDS)	
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DISCUSSION	
Discussion	of	Findings		 This	study	aimed	to	measure	patients’	use,	knowledge	and	perceptions	of	small-scale	pharmacy	compounding	at	an	independent	compounding	pharmacy	in	Mandeville,	Louisiana,	C	and	C	Drugs	Vital	Care.	About	20%,	of	the	pharmacy’s	business	is	comprised	of	compounded	medications,	and	therefore	they	are	widely	used	in	the	store’s	patient	population,	with	some	patients	using	more	than	one	unique	compound.	Anecdotally,	many	of	the	patients	have	gotten	to	know	the	compounding	pharmacist	and	tend	to	be	very	supportive	of	him,	whether	they	get	compounds	or	not.	Specifically,	positive	word-of-mouth,	is	thought	to	be	a	reason	that	new	patients	come	to	C	and	C	Drugs	Vital	Care.	Many	of	the	findings	in	this	study	may	be	explained	by	the	support	for	the	compounding	pharmacist	and	his	practice,	but	further,	in-depth,	longitudinal,	quantitative,	and	qualitative	research	is	needed	to	confirm	these	findings.		For	example,	all	respondents	were	asked	to	report	their	familiarity	with,	and	supportiveness	of,	pharmacy	compounding.	While	there	were	significant	differences	in	familiarity	and	support	between	those	who	did	and	did	not	have	a	connection	to	compounded	medications,	even	those	who	did	not	get	compounded	medications	were	still	familiar	with	or	supportive	of	the	practice.	Indeed,	comments	provided	by	
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some	of	the	respondents	at	the	end	of	the	survey	reiterated	these	findings.	For	example,	one	respondent	noted:		“My	38	year	daughter	has	many	medical	problems,	and	compounding	meds	is	extremely	valuable	to	her	due	to	many	allergies	to	many	ingredients	that	are	used,	although	in	small	amounts,	in	many	drugs,	causing	terrible	side	effects.		Can	get	just	an	effective	med	thru	compounding.”		Another	respondent	less	familiar	with	compounding	noted:		 “I	know	very	little	about	pharmaceutical	compounding.		I	assume	that	it	was	more	common	prior	to	the	mass	production	of	medications	in	recent	times.		Depending	on	the	circumstances,	I	would	think	that	there	is	still	and	will	continue	to	be	a	need	to	pharmaceutical	to	better	serve	patients.”				In	light	of	these	findings,	the	characteristics	of	the	study	sample	should	not	be	ignored.	The	vast	majority	of	the	respondents	described	themselves	as	Caucasian,	highly	educated,	and	making	high	incomes.	Perhaps	this	sample	is	a	reflection	of	the	local	population,	or	it	could	be	a	self-selection	phenomenon.	In	other	words,	this	pharmacy	may	attract	this	type	of	patient	population	because	it	does	make	compounds	that	may	be	more	expensive	and	sometimes	not	covered	by	insurance,	or	this	type	of	population	may	be	more	desiring	of	compounded	
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products.		That	said,	there	was	still	concern	expressed	by	a	respondent	in	her	comment	about	the	cost	of	compounded	medications:		“Why	is	it	so	expensive?		I	used	to	get	my	compounding	cream	for	$35	and	now	it's	over	$200,	therefore	I	no	longer	get	it	because	I	can't	afford	it,	although	it	is	like	"magic"	cream	for	my	pain.		It	really	helps	my	pain	condition	greatly.”		Indeed,	nearly	56%	of	the	83	respondents	reported	not	having	insurance	or	insurance	not	covering	any	of	their	medications.	Interestingly,	those	that	reported	using	a	compounded	medication	in	their	household	more	often	reported	that	a	“drug	not	available	for	the	pharmacy	to	order”	and	“proper	dosage	not	available	for	the	pharmacy	to	order”	were	legally	acceptable	reasons	to	make	a	compounded	medications.	While	a	proper	dosage	not	being	available	is	a	legitimate	reason	to	compound	a	medication,	a	medication	not	being	available	for	the	pharmacy	to	order	is	not.	Additionally,	41	of	the	134	total	respondents	(approximately	31%)	indicated	that	they	believed	personal	preference	was	a	legally	acceptable	use	for	a	compounded	medication.	While	not	statistically	significant,	it	was	found	that	more	respondents	who	did	not	use	compounds	in	their	household	thought	personal	preference	was	legally	acceptable	than	did	respondents	who	did	use	compounded	medications	in	their	household.	In	general,	this	suggests	that	patient	education	on	appropriate	reasons	for	making	compounded	medications	
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may	be	worthwhile.	However,	respondents’	interpretation	of	the	questions	should	be	taking	into	consideration	when	exploring	these	findings.	Another	interesting	finding	was	the	lack	of	knowledge	of	the	NECC	event	that	happened	only	a	few	years	ago.	The	reported	outcome	may	have	been	a	function	of	how	the	question	was	asked.	Many	patients	may	have	remembered	hearing	about	the	many	cases	of	deadly	fungal	meningitis	that	were	contracted	from	an	injection,	but	they	may	not	have	known	that	the	NECC	was	the	organization	responsible	for	compounding	those	tainted	medications.		
Limitations		 The	topic	of	pharmaceutical	compounds	and	their	perception	by	the	surrounding	patient	population	can	be	greatly	affected	by	the	setting,	which	is	the	main	limitation	of	this	study.	The	survey	was	only	administered	at	a	single	pharmacy,	making	it	a	convenience	sample,	rather	than	one	that	is	truly	representative	of	the	whole	state	or	country.	Community	perceptions	may	differ	in	New	England,	as	the	NECC	outbreak	was	a	closer	threat	and	may	have	turned	many	patients	off	of	compounding,	or	in	a	city	that	does	not	have	a	pharmacy	that	offers	compounded	medications,	in	which	case	there	is	a	lack	of	knowledge	of	them.	By	using	only	one	community	to	draw	data	from,	and	by	choosing	a	pharmacy	that	was	very	involved	in	the	practice	of	pharmacy	compounding,	the	study	is	not	generalizable	to	the	rest	of	the	United	States	or	all	patient	populations.		The	motivation	of	patients	within	the	sample	may	also	affect	the	generalizability.	Participation	was	voluntary,	so	it	can	be	expected	that	self-selection	bias	may	result	in	a	much	higher	ratio	of	patients	who	get	compounded	medications	
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participating.	The	results	were	not	adversely	swayed	in	this	study,	but	there	was	a	very	large	percentage	of	responses	that	were	from	patients	with	a	connection	to	compounded	medications.	Pharmacy	patients	may	have	also	felt	more	inclined	to	complete	the	survey	when	they	saw	that	their	participation	would	benefit	one	of	the	employees,	someone	they	knew	personally,	rather	than	a	survey	that	was	conducted	by	someone	they	did	not	know.		
Conclusions	and	Implications		 Overall,	both	groups	of	participants,	those	who	got	compounds	themselves	or	had	a	household	member	who	received	a	compound,	and	those	who	had	no	ties	to	compounds,	had	positive	perceptions	of	compounded	medications,	and	were	familiar	with	the	practice.	Even	those	who	did	not	have	any	connection	to	compounded	medications	appeared	familiar	with	the	practice	of	compounding	medications.	Again,	this	may	be	due	to	the	culture	of	C	and	C	Drugs	Vital	Care	and	the	efforts	by	the	compounding	pharmacist	to	create	an	atmosphere	and	business	that	promotes	pharmacy	compounding	and	positive	perceptions	of	it	by	the	patients.	However,	further,	in-depth,	longitudinal,	quantitative,	and	qualitative	research	is	needed	to	confirm	these	findings.	Future	confirmation	of	these	findings	has	significant	implications	for	pharmacists,	and	how	the	culture	they	create	in	their	pharmacy	can	lead	to	enhanced	knowledge,	positive	perceptions,	and	increased	satisfaction	among	patients.	This	type	of	work	could	be	translated	to	other	compounding	practices	or	any	other	patient-oriented	pharmacy	service	such	as	medication	therapy	management	(MTM).		
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Appendix	A:	Survey	Questions	
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Appendix	B:	Cover	Letter	for	Paper	Survey	Dear	Patient,			My	name	is	Alix	Cawthon,	and	I	am	a	pharmacy	student	at	Ole	Miss.	This	summer	and	fall,	I	am	conducting	a	research	survey	through	the	Sally	McDonnell	Barksdale	Honors	College,	and	I	am	asking	for	your	participation.	This	survey	should	take	no	more	than	7	or	8	minutes	of	your	time.	It	includes	various	demographic	questions,	but	mainly	focuses	on	your	knowledge	and	perceptions	of	pharmacy	compounding,	such	as	the	kind	done	at	C	and	C	Drugs	Vital	Care.	We	are	inviting	all	customers	to	participate,	whether	you	get	compounded	medications	or	not.	Your	willingness	to	participate	in	this	research	will	help	me	better	understand	patients’	understanding	and	attitude	toward	small-scale	pharmaceutical	compounding.			Please	keep	in	mind	that	your	participation	in	this	survey	is	entirely	voluntary.	Your	completion	of	this	survey	does	not	affect	your	patronage	at	this	pharmacy,	or	with	any	of	its	employees.	Your	responses	will	remain	completely	anonymous	and	will	be	examined	along	with	other	respondents’	surveys.			This	study	has	been	reviewed	by	the	University	of	Mississippi’s	Institutional	Review	Board	(IRB).	The	IRB	has	determined	that	this	study	fulfills	the	human	research	subject	protections	obligations	required	by	the	state	and	federal	law	and	University	policies.	If	you	have	any	questions,	please	contact	the	IRB	at	(662)	915-7482.		If	you	have	any	questions	about	the	research	project	specifically,	feel	free	to	contact	me	at	macawtho@go.olemiss.edu,	or	my	advisor,	Dr.	Erin	Holmes,	at	erholmes@olemiss.edu,	or	(662)	915-5914.		Thank	you	in	advance	for	your	participation.			Sincerely,		Alix	Cawthon	
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Appendix	C:	Cover	Letter	for	Electronic	Survey		Dear	Patient,			My	name	is	Alix	Cawthon,	and	I	am	a	pharmacy	student	at	Ole	Miss.	This	summer	and	fall,	I	am	conducting	a	research	survey	through	the	Sally	McDonnell	Barksdale	Honors	College,	and	I	am	asking	for	your	participation.	This	survey	should	take	no	more	than	7	or	8	minutes	of	your	time.	It	includes	various	demographic	questions,	but	mainly	focuses	on	your	knowledge	and	perceptions	of	pharmacy	compounding,	such	as	the	kind	done	at	C	and	C	Drugs	Vital	Care.	We	are	inviting	all	customers	to	participate,	whether	you	get	compounded	medications	or	not.	Your	willingness	to	participate	in	this	research	will	help	me	better	understand	patients’	understanding	and	attitude	toward	small-scale	pharmaceutical	compounding.	You	can	access	the	survey	by	typing	the	link	below	into	your	internet	browser:		
http://tinyurl.com/n7nj89l		Please	keep	in	mind	that	your	participation	in	this	survey	is	entirely	voluntary.	Your	completion	of	this	survey	does	not	affect	your	patronage	at	this	pharmacy,	or	with	any	of	its	employees.	Your	responses	will	remain	completely	anonymous	and	will	be	examined	along	with	other	respondents’	surveys.			This	study	has	been	reviewed	by	the	University	of	Mississippi’s	Institutional	Review	Board	(IRB).	The	IRB	has	determined	that	this	study	fulfills	the	human	research	subject	protections	obligations	required	by	the	state	and	federal	law	and	University	policies.	If	you	have	any	questions,	please	contact	the	IRB	at	(662)	915-7482.		If	you	have	any	questions	about	the	research	project	specifically,	feel	free	to	contact	me	at	macawtho@go.olemiss.edu,	or	my	advisor,	Dr.	Erin	Holmes,	at	erholmes@olemiss.edu,	or	(662)	915-5914.		Thank	you	in	advance	for	your	participation.			Sincerely,		Alix	Cawthon	
	
	
	
	
	
	
